David M. Polen
Polen Capital Management
Polen Capital Management Protagonist Therapeutics Inc stake
total: 588
Polen Capital Management PTGX trades
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 3
- Reduced:
- 1
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Polen Capital Management holds 22,651 Protagonist Therapeutics Inc (PTGX) shares with a market value of roughly $2.78M accounting for 0.02% of the overall portfolio. To date, the estimated cost basis is nearly $65.5 for "buy" trades and estimated average "sell" price is $122.58. Polen Capital Management first purchased PTGX in 2025 Q2, initially acquiring 15,999 shares. Since the initial investment in Protagonist Therapeutics Inc (PTGX), Polen Capital Management has made 4 more transactions.
When did Polen Capital Management buy Protagonist Therapeutics Inc (PTGX)?
Polen Capital Management first invested in Protagonist Therapeutics Inc (PTGX) in 2025 Q2 at the reported quarter-end price of $55.27 per share.
What's the cost basis of Polen Capital Management's PTGX stake?
The estimated cost basis for Protagonist Therapeutics Inc (PTGX) stake is around $65.50 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $65.50
- Weighted AVG sell price:
- $122.58
Polen Capital Management's historical trades in Protagonist Therapeutics Inc
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.02%
|
22,651
|
$122.58
|
$2,776,560
|
-6.93% (-1,686)
|
-0%
|
|
2026 Q1
|
0.02%
|
24,337
|
$105.40
|
$2,565,120
|
+19.60% (+3,988)
|
+0%
|
|
2025 Q4
|
0.01%
|
20,349
|
$87.34
|
$1,777,282
|
+0.12% (+24)
|
+0%
|
|
2025 Q3
|
0.00%
|
20,325
|
$66.43
|
$1,350,190
|
+27.04% (+4,326)
|
+0%
|
|
2025 Q2
|
0.00%
|
15,999
|
$55.27
|
$884,265
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.